Literature DB >> 26587772

Reperfusion-Related Intracerebral Hemorrhage.

Mikito Hayakawa1.   

Abstract

The efficacy of intravenous thrombolysis (IVT) for acute ischemic stroke patients has been well established worldwide, with endovascular therapy performed in patients who have failed or are ineligible for IVT and who have major vessel occlusion. The most feared complication of acute stroke reperfusion therapy is intracerebral hemorrhage (ICH), as these patients have a poor clinical outcome and high mortality. The fundamental mechanisms responsible for reperfusion-related ICH include increased permeability and disruption of the blood-brain barrier. Recombinant tissue plasminogen activator may exacerbate the blood-brain barrier disruption through its pharmacological action during IVT. Furthermore, interactions between the device and the vessel walls and contrast intoxication may also be related to ICH, which includes the occurrence of subarachnoid hemorrhage after endovascular therapy. Numerous factors have been reported to be associated with or to be able to predict ICH, and several scoring systems have been developed for predicting symptomatic ICH (sICH) after IVT. However, a scoring system with enough power to detect an unacceptably high risk of sICH or to provide information on when to withdraw IVT has yet to be definitively established. In current clinical practice, acute stroke patients without contraindications for IVT who have been identified by conventional computed tomography scans normally undergo IVT, irrespective of any clinical predictors of ICH after IVT. Strategies that have been suggested for preventing reperfusion-related ICH in high-risk patients include intensive blood pressure control, tight glycemic control, and the avoidance of early aggressive antithrombotic therapy. If sICH, and especially massive parenchymal hematoma, does occur, hematoma expansion needs to be prevented through the use of tight blood pressure control and other methods. Although evidence of efficacy has yet to be established, surgical removal is performed not only for the purpose of saving lives but also for improving the functional outcome. In order to develop therapeutic strategies for reperfusion-related ICH that will lead to an improved stroke prognosis, further studies are warranted.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26587772     DOI: 10.1159/000437114

Source DB:  PubMed          Journal:  Front Neurol Neurosci        ISSN: 0300-5186


  5 in total

1.  Active Reperfusion Hemorrhage during Thrombectomy: Angiographic Findings and Real-Time Correlation with the CT "Spot Sign".

Authors:  Diogo C Haussen; Ivan M Ferreira; Clara Barreira; Jonathan A Grossberg; Francesco Diana; Simone Peschillo; Raul G Nogueira
Journal:  Interv Neurol       Date:  2018-06-08

2.  Early Reperfusion Following Ischemic Stroke Provides Beneficial Effects, Even After Lethal Ischemia with Mature Neural Cell Death.

Authors:  Yasue Tanaka; Nami Nakagomi; Nobutaka Doe; Akiko Nakano-Doi; Toshinori Sawano; Toshinori Takagi; Tomohiro Matsuyama; Shinichi Yoshimura; Takayuki Nakagomi
Journal:  Cells       Date:  2020-06-01       Impact factor: 6.600

3.  Usefulness of hyperintense acute reperfusion marker sign in patients with transient neurologic symptom.

Authors:  Jihoon Kang; Hyuksool Kwon; Cheol Kyu Jung; Hee-Joon Bae; Moon-Ku Han; Beom Joon Kim; You Hwan Jo
Journal:  Medicine (Baltimore)       Date:  2019-05       Impact factor: 1.817

Review 4.  How Long Are Reperfusion Therapies Beneficial for Patients after Stroke Onset? Lessons from Lethal Ischemia Following Early Reperfusion in a Mouse Model of Stroke.

Authors:  Takayuki Nakagomi; Yasue Tanaka; Nami Nakagomi; Tomohiro Matsuyama; Shinichi Yoshimura
Journal:  Int J Mol Sci       Date:  2020-09-02       Impact factor: 5.923

5.  Potential hemorrhagic risk of endovascular revascularization therapy due to recanalization of the dissected perforator in intracranial internal carotid artery dissection: A case report.

Authors:  Tomohisa Ishida; Hiroyuki Sakata; Masayuki Ezura; Takashi Inoue; Atsushi Saito; Hiroyoshi Suzuki; Teiji Tominaga
Journal:  Surg Neurol Int       Date:  2022-02-25
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.